Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Financial Results

NEXT STORY
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022
PREV STORY
Molecular Partners and Novartis Report Positive Topline Data from Phase 2 Study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Generex Biotechnology Publishes Response to Congressional Letter Calling for COVID-19 Challenge Studies and Alternative Solution to Accelerate Vaccine Development

author_avatar
NASDAQ Market News

Number of shares and voting rights of Innate Pharma as at August 1, 2020

author_avatar
NASDAQ Market News

European Medicines Agency Accepts Astellas’ Marketing Authorization Application for Roxadustat

author_avatar
NASDAQ Market News